Biotechnology company Immutep (ASX:IMM) said its EFTISARC-NEO, a second phase trial of eftilagimod alpha in combination with radiotherapy and KEYTRUDA for patients with soft tissue sarcoma, showed positive data, according to a Thursday filing with the Australian bourse.
The triple combination therapy, based on a preliminary analysis of 21 patients, showed "significant" efficacy in the neoadjuvant setting for resectable soft tissue sarcoma, the filing said.
The study also found an over three-fold increase in tumor hyalinization, a crucial predictor of overall survival, compared with historical results from radiotherapy alone.
The EFTISARC-NEO study, led by the Maria Skłodowska-Curie National Research Institute of Oncology, is expected to enroll 40 patients in the first quarter of 2025, according to the filing.
The new data from the study was presented at the Connective Tissue Oncology Society annual meeting, the filing added.
Immutep shares rose nearly 5% in afternoon trade.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。